The Dangers of Sleeping Pills and Their Most Common Side Effects

Sleeping pills are prescribed in enormous quantities — zolpidem has ranked among the top 25 most prescribed drugs in the United States for years. Yet many people who take them regularly have only a surface-level understanding of what these medications actually do and what the documented risks are. The common understanding — that sleeping pills help you sleep and might make you a little groggy the next day — significantly understates what the clinical and epidemiological literature shows. The risks are real, they are well-documented, and they scale with duration of use and patient age in ways that are rarely communicated at the time of prescription.

The most common side effects

The most frequently reported side effects of sedative-hypnotics are extensions of their intended pharmacological action. Next-day drowsiness affects a substantial proportion of users of z-drugs, benzodiazepines, and antihistamines — it is not a minor inconvenience but can meaningfully impair driving, occupational performance, and reaction time. The FDA reduced recommended doses of zolpidem in 2013 specifically because blood levels the following morning were high enough to impair driving performance even in people who felt alert.

Cognitive impairment is a closely related concern. Z-drugs and benzodiazepines produce anterograde amnesia — the inability to form new memories after taking the drug — in a dose-dependent fashion. This accounts for the clinical phenomenon of patients having no memory of nighttime activities: eating food, sending messages, having conversations. For benzodiazepines, cognitive impairment extends beyond acute amnesia into a more general dulling of processing speed and memory consolidation, particularly with regular use.

Memory disruption is not limited to amnesia during the drug's active window. Sleep itself is essential for memory consolidation, and pharmacologically induced sleep — particularly with z-drugs and benzodiazepines — suppresses slow-wave sleep and REM sleep, the sleep stages most critical for memory processing. Drug-induced sleep is structurally different from natural sleep in ways that matter for next-day cognitive function and long-term brain health.

Complex sleep behaviors and the black box warning

In April 2019, the FDA upgraded its warnings for eszopiclone (Lunesta), zaleplon (Sonata), and zolpidem (Ambien, Ambien CR, Edluar, Intermezzo, Zolpimist) to black box status — its most serious warning level — citing cases of complex sleep behaviors while not fully awake. These behaviors include sleepwalking, sleep-driving, preparing and eating food, making phone calls, engaging in sexual activity, and other behaviors the individual has no memory of upon waking. Fatal accidents and near-fatal incidents were included in the FDA's review. The warning explicitly recommends discontinuing these medications in any patient who has experienced such a behavior.

What makes this particularly concerning is that complex sleep behaviors can occur even on the first dose or at the lowest recommended dose. They do not require long-term use or high doses to manifest. The FDA also notes that combining these medications with other CNS depressants — alcohol, opioids, benzodiazepines, other sedatives — substantially elevates the risk.

Withdrawal syndrome and rebound insomnia

The clinical difficulty of stopping sleeping pills is one of the most underappreciated aspects of their danger profile. When GABA-acting drugs — benzodiazepines and z-drugs — are used regularly, the brain adapts by downregulating GABA-A receptor sensitivity and upregulating excitatory glutamate signaling. When the drug is removed, the brain is left in a hyperexcitable state that produces a withdrawal syndrome: anxiety, agitation, sweating, tremor, and in severe cases — particularly with high-dose or long-duration benzodiazepine use — seizures. Rebound insomnia, which is often more severe than the original sleep complaint, is a near-universal experience upon discontinuation of sedative-hypnotics and is the primary pharmacological mechanism by which these drugs create long-term dependence.

"The rebound insomnia patients experience when trying to stop is pharmacological — it's not a return of the underlying disorder," says Dr. Thomas Osei of Northwestern Sleep Medicine. "But most patients interpret it as evidence they still need the medication, which is how a two-week prescription becomes a ten-year prescription."

Long-term risks: the dementia question

The association between benzodiazepine use and dementia has been a subject of active research since a landmark 2012 BMJ study by Billioti de Gage and colleagues found an association between benzodiazepine use and Alzheimer's disease in elderly patients. A follow-up analysis published in JAMA Psychiatry in 2014 examined 1,796 cases of Alzheimer's disease and found that long-term benzodiazepine users had approximately a 51% increased risk compared to non-users, with the association strengthening with longer duration of use. The causal direction of this association is debated — insomnia and anxiety (common indications for benzodiazepines) are themselves early features of dementia, raising the possibility of reverse causation. But the consistency and magnitude of the signal across multiple studies has prompted most geriatric and sleep medicine guidelines to recommend strongly against benzodiazepine use in older adults.

Falls, fractures, and the elderly

Falls are a leading cause of injury and death in adults over 65, and the contribution of sedative-hypnotics to falls risk in this population is well-established. Benzodiazepines and z-drugs both impair balance, coordination, and reaction time — effects that are often more pronounced in older adults due to pharmacokinetic differences (slower drug clearance, longer half-life). Studies have found that benzodiazepine and z-drug use roughly doubles the risk of hip fracture in older adults. Hip fracture is associated with a 20–30% one-year mortality rate in the elderly — making the falls risk associated with sleeping pills a serious and under-discussed safety concern. The American Geriatrics Society's Beers Criteria, the primary reference for medication safety in older adults, explicitly lists both benzodiazepines and z-drugs as inappropriate for elderly patients.

Drug interactions

Sedative-hypnotics interact dangerously with a wide range of substances. The most clinically significant interactions involve other CNS depressants: opioid analgesics, alcohol, other benzodiazepines, muscle relaxants, and antihistamines. These combinations produce additive or synergistic CNS depression, with the combined respiratory depression of benzodiazepines and opioids being particularly dangerous — a combination that has contributed substantially to opioid overdose deaths. The FDA has issued a separate boxed warning about concurrent use of benzodiazepines and opioids.

The tolerance problem nobody warns about

Perhaps the most clinically significant underappreciated risk is the efficacy problem: most sedative-hypnotics lose meaningful effectiveness within two to four weeks of nightly use. Clinical trials that form the evidence base for approval are almost universally short-term studies of two to four weeks. The drugs are approved for short-term use. Yet prescriptions routinely continue for months or years — a pattern that delivers diminishing benefit while the side effect burden and risks accumulate. For many long-term users, the medication is doing little more than preventing withdrawal insomnia while carrying ongoing risks of cognitive effects, falls, drug interactions, and the other harms described in this article. The non-pharmacological alternative — CBT-I, delivered through programs like Sleep Reset ($297/month, HSA/FSA eligible) — produces durable improvement that does not erode with time and carries none of these risks.

Frequently Asked Questions

What are the most dangerous risks of sleeping pills?

The most dangerous risks include complex sleep behaviors (sleep-driving, sleepwalking) with z-drugs, which can cause serious injury or death and led to an FDA black box warning in 2019; withdrawal seizures with abrupt discontinuation of high-dose or long-term benzodiazepines; falls and hip fracture in elderly patients; and respiratory depression when combined with opioids or alcohol. Long-term risks include cognitive decline and a possible association with dementia.

Do sleeping pills cause dementia?

The evidence is associative rather than definitively causal. A 2014 JAMA Psychiatry study found a 51% elevated dementia risk in long-term benzodiazepine users compared to non-users. The causal direction is debated, since anxiety and insomnia — the conditions being treated — may themselves be early signs of dementia. However, the consistency of the association across multiple large studies has led geriatric and sleep medicine guidelines to strongly recommend against benzodiazepine use in older adults, particularly for long-term use.

How long before sleeping pills become dangerous?

Risk escalates with duration of use. Tolerance typically develops within two to four weeks, at which point the drug is delivering diminishing benefit with accumulating risk. Complex sleep behaviors can occur on the first dose. Falls risk and cognitive impairment are present from the start of use. Long-term risks — dementia association, physical dependence, withdrawal syndrome — accrue over months to years. Clinical guidelines generally recommend limiting sedative-hypnotic use to two to four weeks maximum.

Are sleeping pills more dangerous for older people?

Yes, significantly. Older adults clear these drugs more slowly, meaning blood concentrations remain higher for longer. Cognitive effects are more pronounced and can be severe. Falls risk is dramatically elevated — benzodiazepines and z-drugs roughly double hip fracture risk, and hip fracture has 20–30% one-year mortality in the elderly. The American Geriatrics Society Beers Criteria explicitly lists benzodiazepines, z-drugs, and anticholinergic antihistamines as potentially inappropriate medications in older adults.

What is the alternative to taking sleeping pills long-term?

CBT-I (Cognitive Behavioral Therapy for Insomnia) is the first-line treatment recommended by the American Academy of Sleep Medicine, the American College of Physicians, and the European Sleep Research Society. Multiple meta-analyses show CBT-I is comparable to medication in the short term and significantly superior at one year and beyond. It addresses the underlying behavioral and cognitive mechanisms of insomnia without dependence or side effects. Programs like Sleep Reset ($297/month, HSA/FSA eligible) deliver the full protocol with human coaching.